Adjuvant Taxotere in Patients With High Risk Prostate Cancer Post Prostatectomy and Radiation

Inclusion Criteria: * Patients who have undergone a radical prostatectomy (should have unmeasurable PSA) or radiation therapy for prostate cancer and who have high risk disease as defined by one of the following: * Node positive disease post-operatively * Capsule involvement * Seminal Vesicles involvement * Gleason score ≥ 8 * \>50% of core biopsies that are positive * Clinical Stage T2c and T3 * Pre-op PSA \> 15 plus Gleason score of 7 * Age greater than 18 * ECOG Performance Status 0-1 * Serum creatinine \<= 1.5 mg/dl * Granulocyte count \>= 1500/m3, Hemoglobin \> 8.0 g/dl, and platelet count \>= 100,000/m3 * Total bilirubin \<= ULN * AST, ALT and Alkaline Phosphatase must be within the range allowing for eligibility. * Signed patient informed consent. * Men of childbearing potential must be willing to consent to using effective contraception while on treatment and for three months thereafter. Exclusion Criteria: * Peripheral neuropathy \> grade 1 * History of severe hypersensitivity to Taxotere® or other drugs formulated with polysorbate 80. * Patients who have received previous chemotherapy or are being treated on another clinical trial using an investigational agent. * Active infection within 14 days of beginning treatment * Patients with a serious illness or medical condition, history of significant neurologic or psychiatric or active infection. * Patients with a current malignancy. Patients with prior a history of in situ lobular carcinoma of the breast, basal or squamous cell skin cancer, are eligible.